GPI SpA (IT:GPI)
:GPI
Top Page
GPI SpA
(GPI)
Select Model
Select Model
Rating:51Neutral
Price Target:
€17.00
▲(5.99% Upside)
Action:ReiteratedDate:04/10/26
The score is held back primarily by elevated leverage and inconsistent cash generation despite strong revenue growth. Technicals are moderately supportive with price above major moving averages but only mixed momentum. Valuation is helped by a high dividend yield, though the P/E looks only average given earnings and cash-flow volatility.
Positive Factors
Revenue Growth
Sustained multi-year revenue growth, including a marked step-up in 2025, indicates durable demand and successful commercial execution. Over 2–6 months this supports scale benefits, better absorption of fixed costs, reinvestment capacity and a stronger base for long-term margin improvement.
Negative Factors
Elevated Leverage
Consistently high debt relative to equity raises financial risk and limits strategic flexibility. Over the medium term, the interest burden and potential covenant constraints can crowd out investment in product development or M&A, increasing vulnerability to slower revenue or margin pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained multi-year revenue growth, including a marked step-up in 2025, indicates durable demand and successful commercial execution. Over 2–6 months this supports scale benefits, better absorption of fixed costs, reinvestment capacity and a stronger base for long-term margin improvement.
Read all positive factors
GPI SpA (GPI) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€464.89M
Dividend Yield5.24%
Average Volume (3M)88.12K
Price to Earnings (P/E)28.5
Beta (1Y)0.36
Revenue Growth11.25%
EPS Growth-76.44%
CountryIT
Employees7,812
SectorHealthcare
Sector Strength45
IndustryConglomerates
Share Statistics
EPS (TTM)0.43
Shares Outstanding28,906,881
10 Day Avg. Volume56,776
30 Day Avg. Volume88,124
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)1.51
Price to Sales (P/S)0.87
P/FCF Ratio26.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€16.50Price Target Upside2.87% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.93
Revenue Forecast (FY)€593.20M
GPI SpA Business Overview & Revenue Model
Company Description
GPI S.p.A. operates in the field of social-healthcare IT services and hi-tech services for healthcare markets. The company offers software solutions for health administration, clinical system, health social care, blood and tissue bank, personnel m...
How the Company Makes Money
null...
GPI SpA Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
46
Neutral
Cash Flow
40
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 530.25M | 509.70M | 433.42M | 346.95M | 323.89M |
| Gross Profit | 76.79M | 288.52M | 90.76M | 246.23M | 229.57M |
| EBITDA | 89.03M | 99.93M | 67.96M | 48.60M | 47.35M |
| Net Income | 16.19M | 104.04M | 7.19M | 9.72M | 11.05M |
Balance Sheet | |||||
| Total Assets | 1.09B | 953.91M | 855.13M | 713.24M | 428.51M |
| Cash, Cash Equivalents and Short-Term Investments | 110.31M | 57.63M | 41.53M | 180.92M | 44.87M |
| Total Debt | 485.46M | 289.63M | 427.50M | 262.45M | 208.98M |
| Total Liabilities | 786.20M | 647.71M | 623.78M | 464.29M | 322.28M |
| Stockholders Equity | 305.83M | 308.33M | 232.59M | 248.90M | 105.06M |
Cash Flow | |||||
| Free Cash Flow | 17.23M | -15.48M | 20.99M | -19.68M | -7.89M |
| Operating Cash Flow | 39.10M | 35.91M | 39.75M | 5.58M | 12.75M |
| Investing Cash Flow | -101.55M | 13.96M | -229.95M | -64.91M | -36.04M |
| Financing Cash Flow | 123.89M | -44.77M | 74.30M | 195.01M | -15.94M |
GPI SpA Technical Analysis
Negative
16.04
Price Trends
16.59
Negative
16.50
Negative
16.40
Negative
Market Momentum
-0.06
Positive
43.29
Neutral
36.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:GPI, the sentiment is Negative. The current price of 16.04 is below the 20-day moving average (MA) of 16.32, below the 50-day MA of 16.59, and below the 200-day MA of 16.40, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.29 is Neutral, neither overbought nor oversold. The STOCH value of 36.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:GPI.
GPI SpA Peers Comparison
UnderperformOutperform
Sector (51)
IT:GPI
GPI SpA
16.04
7.62
90.50%
IT:GHC
Garofalo Health Care S.P.A.
4.60
-0.46
-9.02%
IT:EUK
Eukedos S.p.A.
0.65
-0.10
-14.00%
IT:COSMO
Farmacosmo S.P.A.
0.47
-0.23
-32.76%
IT:SVS
Svas Biosana S.p.A.
8.86
1.76
24.79%
GPI SpA Corporate Events
GPI files 2025 accounts and advances merger of Tesi Elettronica
Apr 7, 2026
GPI S.p.A. has made available its 2025 annual financial report, including separate and consolidated financial statements, the management report and sustainability statement, as well as auditors’ reports and explanatory documents for the 29 A...
GPI Calls 2026 Shareholders’ Meeting to Approve 2025 Accounts and Renew Buyback Mandate
Mar 30, 2026
GPI S.p.A. has convened its ordinary shareholders’ meeting for 29 April 2026 in Trento, with voting to be exercised exclusively via an appointed representative under the extended “Cura Italia” framework. The agenda includes appro...
GPI boosts software-led growth, profit margins and dividend as it scales in digital healthcare
Mar 30, 2026
GPI SpA reported 2025 revenues of €546.2 million, up 7% year on year, driven mainly by its Software division, which grew 12.7% to €343.2 million and now accounts for nearly 63% of group revenues. Profitability improved, with EBITDA ris...
Gpi sees pension fund E.N.P.A.I.A. lift stake above 10% as shareholder base consolidates
Feb 25, 2026
Gpi S.p.A., an Italian health‑tech group listed on Euronext Milan Tech Leaders, develops software, technologies and services that support the digital transformation of healthcare and aims to make health systems more sustainable and patient&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.